Denmark-based Zealand Pharma (Zealand) has begun its Phase IIa clinical trial of dasiglucagon in a dual-hormone artificial (or bionic) pancreas system from Beta Bionics for hypoglycaemia.

Dasiglucagon is an analogue of peptide hormone human glucagon, which is produced by alpha cells of the pancreas and released to prevent blood glucose levels dropping low, thereby ensuring a well-functioning metabolic system.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The multiple-dose version of dasiglucagon is aimed to be used in a dual-hormone artificial pancreas system to better manage hypoglycaemia and offer easier options to insulin treated diabetes patients for effective management of their disease.

A dual-hormone artificial (or bionic) pancreas system, designed to automatically deliver insulin and glucagon to people with type 1 diabetes, copies the function of a healthy pancreas.

The Phase IIa trial is the fourth Phase II trial initiated by Zealand this year that intends to determine the safety, efficacy and tolerability of dasiglucagon as part of the Beta Bionics dual-hormone artificial (bionic) pancreas system in adult patients with type 1 diabetes, compared to a recombinant market glucagon.

See Also:

"The Phase IIa trials are expected to pave the way for longer clinical trials, with the multiple-dose version of dasiglucagon in the dual-hormone artificial pancreas system."

The company previously entered into collaboration with Beta Bionics, which is developing the dual-hormone artificial (bionic) pancreas system based on technology conceived at Boston University.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial's principal investigator Steven Russell said: “This Phase IIa study will test the effectiveness of the stable glucagon analogue dasiglucagon in the dual-hormone bionic pancreas, comparing it with the unstable glucagon formulation that we have used in all of our previous studies.

“Demonstrating the effectiveness of a stable glucagon formulation or analogue, such as dasiglucagon, is an essential step towards making a dual-hormone bionic pancreas available to patients."

The Phase IIa trials are expected to pave the way for longer clinical trials, with the multiple-dose version of dasiglucagon in the dual-hormone artificial pancreas system.

Results from both trials are expected in the first quarter of next year.